Evidence for Activation of Toll-Like Receptor and Receptor for Advanced Glycation End Products in Preterm Birth

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left">Extra cellular matrix and cell structure</td><td align="left">CLSTN1 (calsyntenin 1), DSP (desmoplakin), FN1 (fibronectin 1), IGFBP-1 (insulin-like-growth-factor-binding protein 1), LAMA3 (laminin alpha 3), LUM (lumican), and THSD1 (thrombospondin 1)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">Protease</td><td align="left">CTSL2 (cathepsin L2), CST (cystatin), PAI-1 (plasminogen activator inhibitor-1), TIMP1 (tissue inhibitor of metalloproteinase 1), uPA (urokinase plasminogen activator), F2 (prothrombin fragment 2), and SLPI (secretory leukocyte peptidase inhibitor) </td></tr><tr><td align="center" colspan="2"><hr/></td></tr><tr><td align="left">Innate immunity</td><td align="left">defensin-1, defensin-2, S100A8 (Calgranulin A), S100A9 (Calgranulin B), and S100A12 (Calgranulin C) </td></tr><tr><td align="center" colspan="2"><hr/></td></tr><tr><td align="left">Transporter</td><td align="left">Transthyretin (TTR)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Proteins specifically present in preterm birth.

Mediators of Inflammation

tab2

Table 2

Table 2: Evidence for Activation of Toll-Like Receptor and Receptor for Advanced Glycation End Products in Preterm Birth 